3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

NO_LONGER_AVAILABLE

Conditions studied: Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenia (CM)

In brief

Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder which affects the nerve-muscle junction. The major symptoms of LEMS are progressive muscle weakness. Many patients experience other symptoms like dry mouth or impotence. Congenital Myasthenia (CM) is an inherited disorder with similar affects and symptoms. 3,4-Diaminopyridine (DAP) is an experimental drug that has improved strength in some subjects with (LEMS). There are no other accepted treatments for LEMS and DAP has relatively few side effects.

Key facts

Study ID

NCT02012933

Run by

Oregon Health and Science University

Last updated by the study team

2019-12-11

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of LEMS or CM
• If female and over the age of 9, must have a negative pregnancy test, and, if premenopausal, must be willing to practice an effective form of birth control.
• Must be tested and found by ECG not to have a prolonged Q-Tc syndrome.
• Must agree to have a second ECG at the time of peak drug effect.

You may not qualify if…

• Known to have sensitivity to 3,4-DAP
• History of clinical seizures or evidence of seizure activity on screening EEG
• History of severe asthma

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.